Evaluation of Potential for Pharmacokinetic Drug Interaction Between SCH 58235 and Pitavastatin
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 主要终点
- Compare plasma concentrations of SCH 58235 (ezetimibe) and pitavastatin after administration of each drug alone and in combination, using Cmax and AUC(0-24h).
研究概览
简要总结
This study was designed to evaluate the pharmacokinetic interaction and safety of coadministration of SCH 58235 (ezetimibe) and pitavastatin in healthy Japanese adult male subjects or adult male subjects having no obvious disease other than high cholesterol levels.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 65 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy adult male subjects meeting all the criteria below or adult male subjects having no obvious disease other than high cholesterol levels.
- •Aged 20 years or over and 65 years or below when the informed consent is obtained.
- •Weighing 50 kg or over and 80 kg or below on the day of the screening tests, with BMI [Body Mass Index: body weight (kg)/height (m)2] ranging from 16.5 to 27.5.
排除标准
- •Patients meeting any one of the following conditions are excluded from the study.
- •Subjects with the triglyceride value at screening test exceeding 500 mg/dL.
- •Subjects with past history of drug allergy (shock, anaphylactic symptom, and angioedema).
- •Subjects with past history of alcohol or drug dependence.
- •Subjects with past history of mental disorder.
- •Subjects positive in the test for HBs antigen, HCV antibody, or HIV antibody or in the serological test for syphilis.
- •Subjects who used any drug within 2 weeks of investigational product administration in Period
- •Subjects who have drawn more than 400 mL of blood within 12 weeks before administration day in Period
- •Subjects who participated in other study within 16 weeks of investigational product administration in Period 1 and was administered a investigational product.
- •Subjects who cannot take contraceptive measures during the study period (from providing informed consent to completion of Period 3 examination)
- •Subjects who the investigator judges are inappropriate to participate in the study.
研究组 & 干预措施
Group A
SCH 58235 (Period 1) Pitavastatin (Period 2) Coadministration (Period 3)
干预措施: SCH 58235 (Drug)
Group A
SCH 58235 (Period 1) Pitavastatin (Period 2) Coadministration (Period 3)
干预措施: pitavastatin (Drug)
Group B
SCH 58235 (Period 1) Coadministration (Period 2) Pitavastatin (Period 3)
干预措施: SCH 58235 (Drug)
Group B
SCH 58235 (Period 1) Coadministration (Period 2) Pitavastatin (Period 3)
干预措施: pitavastatin (Drug)
Group C
Pitavastatin (Period 1) SCH 58235 (Period 2) Coadministration (Period 3)
干预措施: SCH 58235 (Drug)
Group C
Pitavastatin (Period 1) SCH 58235 (Period 2) Coadministration (Period 3)
干预措施: pitavastatin (Drug)
Group D
Pitavastatin (Period 1) Coadministration (Period 2) SCH 58235 (Period 3)
干预措施: SCH 58235 (Drug)
Group D
Pitavastatin (Period 1) Coadministration (Period 2) SCH 58235 (Period 3)
干预措施: pitavastatin (Drug)
Group E
Coadministration (Period 1) SCH 58235 (Period 2) Pitavastatin (Period 3)
干预措施: SCH 58235 (Drug)
Group E
Coadministration (Period 1) SCH 58235 (Period 2) Pitavastatin (Period 3)
干预措施: pitavastatin (Drug)
Group F
Coadministration (Period 1) Pitavastatin (Period 2) SCH 58235 (Period 3)
干预措施: SCH 58235 (Drug)
Group F
Coadministration (Period 1) Pitavastatin (Period 2) SCH 58235 (Period 3)
干预措施: pitavastatin (Drug)
结局指标
主要结局
Compare plasma concentrations of SCH 58235 (ezetimibe) and pitavastatin after administration of each drug alone and in combination, using Cmax and AUC(0-24h).
时间窗: Day 7 of each period
次要结局
- Compare plasma concentrations of SCH 58235 (ezetimibe) and pitavastatin administration of each drug alone and in coadministration, using Tmax, plasma concentration 24 h after last dose, and AUC(I).(Day 7 of each period)
- Adverse events, laboratory tests results, and vital signs.(Throughout study)